ARTICLE | Deals
AstraZeneca, Silence partner to bring siRNA therapies to extrahepatic tissues
AZ, Silence rekindle an old partnership with new deal for siRNA therapeutics
March 25, 2020 11:44 PM UTC
Updated on Mar 28, 2020 at 2:41 AM UTC
Thirteen years after they first teamed up, AstraZeneca and Silence are giving their partnership another shot with a new $80 million deal to develop siRNA therapeutics targeting the liver and extrahepatic tissues.
The deal is the second for AstraZeneca plc (LSE:AZN; NYSE:AZN) this year in RNA therapeutics as the company establishes its foothold in the modality through external innovation. ...